Could a COPD drug ease rheumatoid arthritis?
NCT ID NCT07632846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding roflumilast to standard treatment can reduce joint pain and swelling in people with active rheumatoid arthritis. About 50 adults aged 18-60 will take either roflumilast or a placebo for 12 weeks. Researchers will measure changes in disease activity and blood markers of inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Pharmacy, Horus University in Egypt
RECRUITINGAl Mansurah, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers